Save billions or stick with Humira? Drug brokers steer Americans to the costly choice

Humira has enjoyed high-priced U.S. exclusivity for 20 years. Its challengers could save the health care system $9 billion and herald savings from the whole class of drugs called biosimilars.

Related Keywords

New York ,United States ,Brooklyn ,Kentucky ,Denmark ,California ,Poland ,Tennessee ,United Kingdom ,Americans ,American ,Michael Thompson ,Cora Opsahl ,Richard Gonzalez ,Greg Baker ,Coherus Biosciences ,Antonio Ciaccia ,Alex Jung ,Siddharth Singh ,Madelaine Feldman ,Mark Cuban ,Rachel Shubert ,Juliana Reed ,Kaiser Permanente ,Mary Beth Lang ,Keith Athow ,Kevin Ali ,Paul Holmes ,American College Of Rheumatology ,Kroger ,Midwest Business Group On Health ,Biosimilars Forum ,American Gastroenterological Association ,Health News ,National Alliance Of Healthcare Purchaser Coalitions ,Service Employees International Union ,Bj Health Fund ,Arthur Allen ,Williams Barber Morel ,Express Scripts ,Federal Trade Commission ,Blue Shield ,Cost Plus Drugs ,Sue Lee ,National Alliance ,Healthcare Purchaser ,Midwest Business Group ,Marcus Snow ,American College ,New Orleans ,Gastroenterological Association ,Inflation Reduction Act ,Rich Lieblich ,